KCRS21 Presentations & Video

Welcome and Fireside Chat with Gordon Freeman and Arlene Sharpe

Bryan Lewis, KidneyCAN President
Toni Choueiri, KCRS Co-Chair, Dana-Farber Cancer Institute
Hans Hammers, KCRS Co-Chair, University of Texas Southwestern.

Our Lives with Immunology
Gordon Freeman, Dana-Farber Cancer Institute
Arlene Sharpe, Harvard Medical School
(begins at 4:55)

Tumor evolution/mechanisms of lethality

Moderated by Scott Tykodi, UW Medicine & Eric Jonasch, MDACC

  Targeting the Osteogenic Niche for Preventing Kidney Cancer Bone Metastasis Progression
– Robert Satcher, M.D. Anderson Cancer Center
(begins at 1:40)

  Epigenetic Modifications of Cytosines in Clear Cell Kidney Carcinogenesis and Survival
– Lucas Salas, Dartmouth College
(begins at 14:43)

  Analysis of Transcriptional Profiles During the Evolution of ccRCC from Premalignant to Malignant Lesions
– Olivia Lombardi, University of Oxford
(begins at 28:43)

  Dissecting the Periostin-Directed Metastatic Cross Talk in Clear Cell Renal Cell Carcinoma
– Lily Wu, University of California, Los Angeles
(begins at 45:55)

Innovative non-immune therapy related therapeutics and monitoring

Moderated by Eric Jonasch, MDACC & Moshe Ornstein, Cleveland Clinic

  The Investigation of Ferroptosis as a Novel Therapeutic Paradigm for Kidney Cancer
– Mei Yee Koh, Kuda Therapeutics, Inc.
(begins at 1:42)

  Exploiting Cholesterol Metabolism to Treat Primary and Metastatic Renal Carcinoma
– M. Celeste Simon, University of Pennsylvania
(begins at 16:40)

  Monitoring Disease Burden and Biology Using Tumor Cell-Free DNA in Metastatic Kidney Cancer
– Scott Haake, Vanderbilt University Medical Center
(begins at 31:27)

  Exploiting Epigenetic Dysregulation to Identify Targetable Vulnerabilities in ccRCC
– Abhishek Chakraborty, Cleveland Clinic Foundation
(begins at 47:24)

Non-Clear Cell RCC

Moderated by Nizar Tannir, MDACC & Ari Hakimi, MSKCC

  Development of Mouse Models for Variant RCC Histologies
– Giannicola Genovese, MD Anderson Cancer Center
(begins at 2:06)

  Unlocking the Human Relevance of a New Genetic Papillary Renal Cell Carcinoma Mouse Model
– Richard Link, Baylor College of Medicine
(begins at 10:56)

  The Pathogenesis and Therapy of Chromophobe Renal Cell Carcinoma
– Elizabeth Henske, Brigham and Women’s Hospital
(begins at 20:20)

  Genomic and Functional Analysis of Translocation Renal Cell Carcinoma
– Srinivas Viswanathan, Dana-Farber Cancer Institute
(begins at 26:28)

  A Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma
– Pavlos Msaouel, MD Anderson Cancer Center
(begins at 34:10)

Immunotherapy Advances and Research

Moderated by Hans Hammers, UTSW & Michael Atkins, GLCCC

  Immunotherapy Based Biomarkers that Could Relate or Inspire RCC Research
– Janis Taube, Johns Hopkins University
(begins at 13:00)

  Understanding CD8+ T-Cell Specificity and Function in Renal Cell Carcinoma
– David Braun, Dana-Farber Cancer Institute
(begins at 35:15)

  Integrated Analysis of Somatic Genomic Mutations and Antigen Presentation as Predictive Biomarkers for Combination Immunotherapy in Kidney Cancer
– Chung-Han Lee, Memorial Sloan Kettering Cancer Center
(begins at 50:51)

  Combining Locally Administered Ipilimumab with a Personalized Neoantigen Cancer Vaccine to Improve T-Cell Priming and Antitumor Immunity in High-Risk Renal Cell Carcinoma
– Catherine Wu, Dana-Farber Cancer Institute
(begins at 1:04:04)

  Overcoming Kidney Cancer Resistance to Immune Checkpoint Inhibitors
– Kiyoshi Ariizumi, UT Southwestern Medical Center
(begins at 1:21:49)

Clinical and Scientific Updates in Kidney Cancer

Moderated by Toni Choueiri, DFCI & Brian Rini, VUMC

  Recent Clinical Trial Results
– Elizabeth Plimack, Fox Chase Cancer Center
(begins at 0:46)

  Translational Research Updates in Renal Cancer
– Tom Powles, Barts Cancer Centre
(begins at 19:30)

  Trials in Progress and Their Significance
– Robert Motzer, Memorial Sloan Kettering Cancer Center
(begins at 43:00)

Abstract Oral Presentations

Moderated by Sumanta Pal, CHCCC & Rana McKay, UC San Diego

  A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (the CLEAR study)
– Toni Choueiri, Dana-Farber Cancer Institute
(begins at 0:29)

  Characterization of responders in the phase 3 CheckMate 9ER trial: nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced renal cell carcinoma
– Amishi Shah, MD Anderson Cancer Center
(begins at 11:22)

  Pembrolizumab (pembro) vs placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma (RCC): randomized, double-blind, phase 3 KEYNOTE-564 study
Toni Choueiri, Dana-Farber Cancer Institute and presented by Tom Powles, Barts Cancer Centre
(begins at 26:00)

  Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: a randomized phase Ib study and in-depth analysis of gut microbiome evolution
– Nazli Dizman, Yale New Haven Hospital
(begins at 36:50)

  Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma
– Ziad Bakouny, Dana-Farber Cancer Institute
(begins at 44:39)

  Generation of an in vivoCRISPR/Cas9-based ccRCC model using AAV
– Laura Stransky, Dana-Farber Cancer Institute
(begins at 59:33)

Abstract Rapid Presentations

Moderated by Sumanta Pal, CHCCC & Rana McKay, UC San Diego

  Potential Role of Seleno-L-Methionine (SLM) in Stabilization of Tumor Vasculature and Enhanced Efficacy of Axitinib in Previously Treated Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
– Yousef Zakharia, University of Iowa
(begins at 0:40)

  Real-world treatment patterns and outcomes of front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab for metastatic clear cell renal cell carcinoma
– Kevin Zarrabi, Fox Chase Cancer Center
(begins at 7:55)

  Characterizing the immune response in patients with renal cell carcinoma (RCC) following COVID-19 vaccination
– Jasnoor Malhotra, City of Hope Comprehensive Cancer Center
(begins at 14:25)

  Histologic Growth Patterns in Nephrectomy Specimens of Clear Cell Renal Cell Carcinoma Inform Tumor Evolution
– Nicolas Sayegh, Huntsman Cancer Institute
(begins at 18:33)

  Transcriptomic analysis predicts resistance and toxicity in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)
– Lucia Carril-Ajuria, University Hospital 12 de Octubre
(begins at 29:15)

  Ultra-sensitive ctDNA distinguishes complete response (CR) and partial response (PR) with immunotherapy in metastatic renal cell carcinoma (mRCC) patients
– Alex Chehrazi-Raffle, City of Hope Comprehensive Cancer Center
(begins at 34:50)

  Seq-ing the source of radiation-induced anti-tumor immunogenicity in renal cell carcinoma patient tumors
– Jason Muhitch, Roswell Park Comprehensive Cancer Center
(begins at 40:29)

  Multiplex analysis of the tumor microenvironment (TME) in papillary renal cell carcinoma (pRCC) suggests a role of macrophages in therapeutic response
– Nicholas Salgia, University at Buffalo
(begins at 46:07)